Psychedelics are big business for the drug market, with an estimated 2029 valuation of $11.82 billion USD (compared to $4.87 billion in 2022). While this rapid growth is indicative of the excitement surrounding positive study results for the treatment of PTSD, treatment-resistant depression and other conditions, these therapies pose numerous challenges throughout the clinical trial process. With the right-fit partner, though, solutions flex to the needs of your unique psychedelics trial, taking into account both standard best practices and the specific difficulties with trials of this type. A ..read more

Psychedelics are big business for the drug market, with an estimated 2029 valuation of $11.82 billion USD (compared to $4.87 billion in 2022). While this rapid growth is indicative of the excitement surrounding positive study results for the treatment of PTSD, treatment-resistant depression and other conditions, these therapies pose numerous challenges throughout the clinical trial process. With the right-fit partner, though, solutions flex to the needs of your unique psychedelics trial, taking into account both standard best practices and the specific difficulties with trials of this type. A ..read more

Improving time to market is an ongoing priority for pharmaceutical, biotech and combination drug sponsors — especially for small- to medium-size organizations — and trial timing hinges on effective and efficient patient recruitment. Few things can stall your clinical trial progress quite as successfully as patient enrollment issues, and few things can cause patient enrollment issues quite as successfully as poor site selection. This leads to mounting problems, because “sites unable to recruit enough patients increase the length of the enrollment period and become an economic burden,” as summe ..read more

Choosing the right CRO for your clinical research is a big decision, and it’s one we’ve explored before (find more details here). Within that earlier examination, it’s clear that one of the major components guiding success at each step of your project is the team supporting you. While some CROs lure you in with their top experts and then saddle you with an inexperienced team, more flexible organizations, like PRC Clinical, provide the best people for each job, bringing their A team to your every challenge. Better results are guided by individuals who not only excel at communication and suppor ..read more

“Since 2003, our experienced team has been providing a hands-on approach for trials because we understand that therapeutic areas like regenerative medicine, CNS and ophthalmology require exceptional attention to the study details.” — Curtis Head, CEO & Co-Founder, PRC Clinical An Interesting Time to Be a CRO In the early 2000s, the CRO industry was still adjusting to a period of astonishing growth and M&A activity in which the essential relationship between CROs and sponsors had evolved. While services had previously been contracted mostly to provide additional capacity for spillover ..read more

The post The Right CRO: Vetting Process for Your Complex Therapeutics appeared first on PRC Clinical ..read more

PRC Clinical and CROs worldwide depend on networks of healthcare professionals and research sites to advance new drugs and disease treatments through clinical trials. Whether you’re an experienced research center or you plan to add research under your existing site practice, the developing groundbreaking personalized therapies and cures requires quality sites. Although high-performing sites are in demand, there are about twice as many sites seeking work than there is work available. To become part of the high-performing group, make sure your facility has what it takes to enroll the right parti ..read more

It’s no secret that COVID-19 has caused an unprecedented disruption for sponsors, investigators, and patients in 2020. According to a recent article in Nature Reviews Drug Discovery, “around 1,000 organizations have reported trial disruption, consistent with a reported ~80% decrease in new patients entering trials per site in April 2020 compared with April 2019.” Although there has been a slight trend toward trial resumption, many trials continue to suffer from slow patient enrollment. As a recent white paper presenting the findings of Veeva Systems 2020 Study Start-Up Pulse Report highlights ..read more

Thousands of years before the term regenerative medicine (RM) was coined, the theory of regeneration was the stuff of legends. Dating back to the 8th century B.C., this concept was depicted in the ancient Greek myth as recounted by Hesiod wherein the Greek Titan, Prometheus, stole fire from Olympus to aid mankind. As punishment, the immortal was banished to the Carpathian Mountains and chained to a rock to be tortured for thousands of years. Each night Prometheus was visited by an eagle that would consume his liver only for it to grow back the following day. Subsequently the eagle would return ..read more

September is World Alzheimer’s Month, an international campaign organized by Alzheimer’s Disease International (ADI) to raise awareness and challenge the stigmas surrounding the disease. Characterized by progressive memory loss along with neuropsychiatric symptoms, Alzheimer’s disease (AD) affects two out of every three people or roughly 13 million people globally. An irreversible progressive neurological disorder, AD is a form of dementia that severely affects the quality of patient’s lives. Since its discovery in 1909, hundreds of treatments have been tested, but there is still no cure for t ..read more